Bio News
Hanmi Pharmaceutical recorded consolidated operating profit of KRW 131 billion in the second quarter, a 116.9% increase from the same period a year earlier. Revenue rose 29.3% to KRW 467.2 billion during the same period, while cumulative R&D investment in the first half totaled KRW 125.5 billion, equivalent to 14.6% of revenue. The company plans to hold an investor relations (IR) briefing after the disclosure to announce its finalized results.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
